The “up-and-coming diet drug” Viking (VKTX.US) drug enters the late stages of development, and the “Nolie” stock price fell in shock
As the Viking diet pill entered the later stages of clinical trials, Eli Lilly and Novo Nordisk stock prices declined.
Viking Sends Lilly, Novo Lower as Obesity Drug Enters Late-stage Program
What Lies in Store for Healthcare ETFs in Q2 Earnings?
Amgen, Garmin Among Relative Market Leaders Poised to Outperform in Coming Months: BTIG
Investors in Amgen (NASDAQ:AMGN) Have Seen Splendid Returns of 122% Over the Past Five Years
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $360
